Natureza’s findings contribute to new perspectives in antimicrobial development by addressing long-standing challenges associated with development cost and resistance pressure. By focusing on formulation-based antimicrobial strategies rather than traditional systemic drug discovery, this approach supports a more sustainable path for advancing antimicrobial technologies. This would allow a new investment environment to emerge that would encourage the development of new, much-needed antibiotics.

This work is protected by issued and pending U.S. and foreign patents.